Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2020-10-21 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings
2020-10-21 English
Opthea Announces Closing of US Initial Public Offering 251 pages 3.2MB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 21 October 2020 announcing the closing of an initial public offering (IPO) of American Depositary Shares (ADS) in the United States by Opthea Limited. It includes detailed information about the offering size, price, underwriters, listing details, and a prospectus summary with a table of contents covering financial data, risk factors, management discussion, and other IPO-related disclosures. The document is a formal announcement of a capital raising event and includes a prospectus, which is typical for IPOs and other financing activities. There is no indication that this is a full annual or interim report, earnings release, or other types of filings. The primary focus is on the financing event and capital structure changes due to the IPO. Therefore, the document best fits the category of Capital/Financing Update (CAP).
2020-10-20 English
Ceasing to be a substantial holder 10 pages 165.4KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 605' and references the Corporations Act Section 671B, which pertains to notices of ceasing to be a substantial holder. The content details changes in relevant interests of a substantial shareholder, including dates, nature of changes, and securities affected. It includes appendices with prescribed information about agreements related to securities borrowing and lending. There is no financial performance data, earnings information, management discussion, or regulatory compliance filings beyond the substantial holder notice. This type of document is a notification of changes in significant share ownership levels, specifically ceasing to be a substantial holder, which aligns with the category 'Major Shareholding Notification' (MRQ). The document length and detail confirm it is the actual notice, not just an announcement or certification.
2020-10-20 English
424B4
Regulatory Filings
2020-10-19 English
Change in substantial holding 2 pages 129.5KB
Regulatory Filings
2020-10-19 English
Regulatory Filings 2020
Regulatory Filings
2020-10-19 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.